)
)
The Pharmacy and Poisons Board (PPB) has cautioned Kenyans against the unsupervised or off-label use of semaglutide-containing medicines, commonly marketed under brand names such as Ozempic, saying the injections are prescription-only and may cause serious harm when used without medical oversight.
The regulator issued the safety alert on August 19, 2025 as demand for the drug for weight loss has grown.
Regulator's guidance on approved use
The PPB reminded the public that semaglutide is approved in Kenya for the treatment of adults with type 2 diabetes mellitus whose condition is insufficiently controlled by other measures, and not for general weight management.
)
)
)
Pharmacy and Poisons Board CEO Dr. F. M. Siyoi
Internationally, a higher-dose formulation of semaglutide has been approved for chronic weight management under the brand name Wegovy by the US Food and Drug Administration, but that licence and dosing differ from Ozempic’s authorisation for diabetes.
READ ALSO: Gov't bans importation & sale of drugs certain drugs: Here is what you should know
Reported adverse effects
In its statement the board listed several adverse outcomes linked to inappropriate use.
Reported risks include;
Hypoglycaemia (low blood sugar).
Eye conditions.
Gastro-oesophageal reflux (acid).
Intestinal obstruction.
The PPB said that while semaglutide can have clinical benefits when prescribed and monitored, its off-label use may result in serious health outcomes.
Members of the public are urged not to self-prescribe or obtain injections from unregulated sources.
READ ALSO: Pharmacy and Poisons Board quarantines drug
Counterfeit Ozempic concerns
The regulator also warned about the circulation of falsified or substandard semaglutide products.
The PPB has previously issued alerts about counterfeit Ozempic pens in the market and advised consumers to report suspect products.
)
Pharmacy and Poisons Board.
The World Health Organization has likewise issued global alerts after detecting falsified semaglutide batches in several countries.
Those factors, the board said, increase the risk that users purchasing injections privately may receive ineffective or harmful preparations.
READ ALSO: Pharmacy and poisons board recalls common blood pressure drug from all chemists, hospitals
Reporting channels
Kenya’s medicines regulator provided channels for reporting adverse effects and suspect products, including its pharmacovigilance portal, an email address and a helpline.
The PPB asked anyone who experiences side effects or who has information about potentially poor-quality or illicitly supplied semaglutide products to submit reports through the following official reporting channels of the Pharmacy and Poisons Board (PPB);
Pharmacovigilance Electronic Reporting System pv.pharmacyboardkenya.org
Email: pv@ppb.go.ke
Phone No: +254 795 743 049
USSD Code (For the Public): *271#
The PPB’s alert comes amid broader international regulatory activity.
Regulators such as the US Food and Drug Administration have warned against unapproved or illegally marketed GLP-1 products and urged consumers to avoid purchasing medicines sold outside authorised supply chains.
The Kenyan board said such global concerns reinforce the need for prescriptions and clinician supervision when using semaglutide-class medicines.
READ ALSO: Gov't recalls drug used to treat ulcers & H.pylori over packaging mix-up
Legal obligations for clinicians and pharmacies
Health professionals and pharmacy operators in Kenya are bound by national law to dispense prescription medicines only against a valid prescription.
The PPB’s advisory reiterates that obligation and stresses that decisions about use, dosing and follow-up should be made by qualified clinicians to reduce avoidable harm.